Therapeutics News and Research

RSS

Research paper highlights implementation of infectious disease curriculum in Boston Public Schools

A research paper published online this month in Academic Medicine highlights the successful development, implementation, and effects of an infectious disease curriculum that has now been piloted in five Boston Public Schools.

27 Mar 2013

Three Ludwig scientists named as Fellows in inaugural class of AACR Academy

Three Ludwig scientists were named as Fellows in the inaugural class of the AACR Academy, the most prestigious honor bestowed by the American Association for Cancer Research.

27 Mar 2013

Study provides important insight into how BMT treatment works in patients with MS

A new study by Multiple Sclerosis researchers at three leading Canadian centres addresses why bone marrow transplantation has positive results in patients with particularly aggressive forms of MS.

27 Mar 2013

Scientists find new mechanism for guiding growth of nerves

A new mechanism for guiding the growth of nerves that involves cell-death machinery has been found by scientists at the University of Nevada, Reno that may bring advances in neurological medicine and research.

26 Mar 2013

UCI study finds novel molecular mechanism that helps trigger formation of long-term memory

UC Irvine neurobiologists have found a novel molecular mechanism that helps trigger the formation of long-term memory. The researchers believe the discovery of this mechanism adds another piece to the puzzle in the ongoing effort to uncover the mysteries of memory and, potentially, certain intellectual disabilities.

26 Mar 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Investigators at the University of Alabama at Birmingham (UAB) have unlocked another piece of the puzzle surrounding idiopathic pulmonary fibrosis, an often fatal lung disease with no cure and no effective treatments.

25 Mar 2013

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088.

24 Mar 2013

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.

22 Mar 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.

21 Mar 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013

Multipotent stem cells in deer antler may have regenerative uses in veterinary medicine

A team of researchers in Seoul, Korea have reported finding evidence that deer antlers - unique in that they regenerate annually - contain multipotent stem cells that could be useful for tissue regeneration in veterinary medicine.

20 Mar 2013

Protein derived from Pacific cod may inhibit prostate cancer, researchers say

Researchers at the University of Maryland School of Medicine have identified a peptide, or protein, derived from Pacific cod that may inhibit prostate cancer and possibly other cancers from spreading, according to preclinical research published online in the Proceedings of the National Academy of Sciences.

20 Mar 2013

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Therapeutics News and Research

Research paper highlights implementation of infectious disease curriculum in Boston Public Schools

Three Ludwig scientists named as Fellows in inaugural class of AACR Academy

Study provides important insight into how BMT treatment works in patients with MS

Scientists find new mechanism for guiding growth of nerves

UCI study finds novel molecular mechanism that helps trigger formation of long-term memory

arGEN-X advances ARGX-112 into formal preclinical development

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

Multipotent stem cells in deer antler may have regenerative uses in veterinary medicine

Protein derived from Pacific cod may inhibit prostate cancer, researchers say

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

Promising studies for Parkinson's to be presented at 65th AAN meeting

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News